ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

XBIO Xenetic Biosciences Inc

4.0899
0.314 (8.32%)
After Hours
Last Updated: 17:17:40
Delayed by 15 minutes

Period:

Draw Mode:

Volume 667
Bid Price 3.77
Ask Price 4.50
News -
Day High 4.1299

Low
2.55

52 Week Range

High
5.97

Day Low 3.75
Company Name Stock Ticker Symbol Market Type
Xenetic Biosciences Inc XBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.314 8.32% 4.0899 17:17:40
Open Price Low Price High Price Close Price Prev Close
3.75 3.75 4.1299 4.0899 3.7759
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
20 667 $ 4.04 $ 2,696 - 2.55 - 5.97
Last Trade Time Type Quantity Stock Price Currency
16:00:00 2 $ 3.81 USD

Xenetic Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.3M 1.54M - 2.54M -4.14M -2.68 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Xenetic Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No XBIO Message Board. Create One! See More Posts on XBIO Message Board See More Message Board Posts

Historical XBIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.064.303.743.812,5690.02990.74%
1 Month3.854.743.744.346,8810.23996.23%
3 Months3.664.743.33014.165,7470.429911.75%
6 Months3.064.742.86963.865,1991.0333.66%
1 Year4.6215.972.553.6417,122-0.5311-11.49%
3 Years19.6056.802.40129.40941,726-15.51-79.13%
5 Years14.30168.8952.40126.49746,185-10.21-71.40%

Xenetic Biosciences Description

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer.

Your Recent History

Delayed Upgrade Clock